36
5 th World Psoriasis & Psoriatic Arthritis Conference 2018
treatment in Germany 2016 / 17( 2) Comparison of health care quality indicators between the surveys 2004 / 05, 2007, 2013 / 14 and 2016 / 17. Methods: Nationwide, non-interventional, cross-sectional studies. In each survey between 71 and 130 centers included patients and data from patients and dermatologists were obtained from a minimum of 1500 patients per survey. Quality of care indicators were severity of the psoriasis( PASI and proportion of patients with PASI > 20, indicating high severity), quality of life( DLQI and proportion of patients with DLQI > 10, indicating strong impairments in quality of life), previous systemic therapy and inpatient treatment in the last five years. Results: Between January 2016 and December 2017 n = 1827 patients from 93 dermatological centers were included in the recent survey( mean age 51 years, 45.2 % female). 7.5 % had severe psoriasis( PASI > 20) compared to 9.2 % in 2013 / 14, 11.6 % in 2007 and 17.8 % in 2004 / 05. The mean PASI was 7.3 compared to 8.1 in 2013 / 14, 10.1 in 2007 and 11.4 in 2005. The mean DLQI was 6.1 compared to 5.9 in 2013 / 14, 7.5 in 2007 and 8.6 in 2005. 21.4 % reported a strongly impaired quality of life( DLQI > 10) compared to 21.3 % in 2013 / 14, 28.2 % in 2007 and 34.0 % in 2005. 59.5 % of all participants stated that they had received systemic therapy at least once within the last five years compared to 59.5 % in 2013 / 14, 47.3 % in 2007 and 32.9 % in 2005. 18 % received inpatient hospital treatment within the last five years at least once, compared to 20.1 % in 2013 / 14, 20.1 % in 2007 and 26.9 % in 2005. Conclusions: It can be assumed that health care quality for psoriasis patients in Germany has improved within the last 12 years.
P083
GLOBAL PSORIASIS ATLAS – WORK STREAM 2 Matthias Augustin, Nirohshah Suthakharan University Medical Center Hamburg, Institute for Health Services Research in Dermatology and Nursing( IVDP)
Introduction: Psoriasis is a common, chronic and non-communicable skin disease with an immensely negative impact on people’ s lives. There is a lack of standardized case-definition or methodology leading to a wide variation in the prevalence estimate between 0.09 % and 11.43 %. To tackle this knowledge deficit and in response to the WHO Global report on Psoriasis( 2016), the Global Psoriasis Atlas( GPA) will be a first-ever online leading epidemiological database on psoriasis. It will inform research, policy and health care provision worldwide. GPA provides a detailed disease prevalence and incidence as well as information on access to treatment, comorbidities and cost to society which will enable extensive comparisons between countries over time. Furthermore, it will provide accurate health data for decision makers, stakeholders and patients worldwide. Objectives: The GPA includes two Work Streams( WS) Teams. WS1 is conducting extensive literature review on psoriasis. In this paper the WS2 is explaining the development of methodology to serve the framework for compiling the GPA data. Methods: Currently, data sources are being collected in two phases and for the selection of data sources an in- / exclusion criteria were developed and followed. Firstly, a global online survey on data source identification is being conducted in > 150 countries worldwide addressed to dermatologists and non-dermatologists. The questionnaire identifies local, regional and national data sources including registries, research institutes, projects, publications and other relevant sources supporting the GPA project. Secondly, Desk research on the same data sources is being conducted. Discussion on the following aspects: identification of non-published sources, integration of different sources, solving interpolation issues of hard-to-reach areas and creating database. Results: Desk research has identified potential data sources from 199 countries which includes 194 ministries of health, 97 registries, 84 patient associations, 32 statistic institutes, 25 Public Health organizations, 230 research institutes( general / psoriasis specific), 13 claim data sources and 261 publications on psoriasis. The internal pilot for the global online surveys has been completed by an international expert team for further improvement. Currently, the surveys are being sent out to dermatologists and non-dermatologists. On a monthly base, both work streams are updating each other about their achievements and issues. Conclusion: In the next steps of Work Stream 2, a database will be created in order to insert all identified data sources. Information from identified data sources will be used to contact( via email) the responsible persons to access this data. Additionally, survey responses will be analyzed and added in the database. This database will be updated regularly and extended to include comorbidities in future.
P084 GLOBAL BURDEN OF DISEASE: A SYSTEMATIC LITERATURE REVIEW ON DISABILITY WEIGHTS FOR
SKIN DISEASES Nirohshah Suthakharan, Matthias Augustin University Medical Center Hamburg, Institute for Health Services Research in Dermatology and Nursing( IVDP)
Introduction: Skin diseases account for one of the most common human illnesses globally but in the recent Global Burden of Disease( GBD) study, psoriasis, for example, ranked 144 out of 174 conditions in the DALY rankings. Two components of DALY calculation are prevalence of the disease and disability weight factor. The derivation of disability weight( DW) factor depends on many factors which can lead to wide range of results. GBD methodology can significantly underestimate the skin disease burden. Objective: To understand the currently used DWs of skin diseases in-depth and if these current records of DWs can be solely based on a survey that was conducted on the general population. Methodology: A systematic literature review was performed to answer the research questions. Comprehensive search of eligible scientific and grey publication in English, from 2007 to 2017, were conducted in PubMed and EMBASE( Ovid). The studies included were based on 16 skin condition and other diseases indicating a re-estimation, alternative approach( also besides DALY) to DWs. 20 relevant studies were included and have been elaborated in the review based on a‘ conceptual model of assessing DWs and its design choices’ by Haagsma et al., 2014. The health state descriptions, panel composition, and valuation methods used to derive DWs in these studies is discussed in detail. Results: There was scarce literature available for skin diseases in particular. DW value depends on and can vary with the panel composition: general public, health experts or patients. The health state description whether disease specific or generic, with or without label, describing the course of condition over a period or only temporarily, can all influence the panel members’ decision. The valuation methods paired comparison, population health equivalence, visual analogue scale, standard gambling or person / time trade-off can alter the results to a great extent. The contextual differences across the countries can also make a difference in the calculation. The inclusion of certain skin conditions / health states under other medical specialties can be a major factor leading to underestimation of overall skin disease burden worldwide.
P085 MIR-499 POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO PSORIATIC ARTHRITIS –
PRELIMINARY STUDY Renata Sokolik 1, Jerzy Świerkot 1, Milena Iwaszko 2, Mikołaj Kozłowski 1, Lucyna Korman 1, Piotr Wiland 1, Katarzyna Bogunia-
Kubik 2 1
Department and Clinic of Rheumatology and Internal Medicine of Wroclaw Medical University, 2 Laboratory of Clinical Immunogenetics and www. medicaljournals. se / acta